Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Measurable disease by CT or MRI.~* At least 1 target lesion to be used to assess response as defined by GOG RECIST criteria.~* ECOG performance status of 0 or 1.~* Patient provides voluntary written informed consent.~* At least 18 years of age.~* Negative serum pregnancy test.~* Recovered from any recent surgery for at least 30 days and is free of active infection.~* Received the following prior therapy at time of enrollment:~* Must have had 1 prior platinum-based chemotherapeutic regimen containing carboplatin, cisplatin or organoplatinum. Initial therapy may have included high-dose therapy, consolidation, or extended therapy. Patient should be defined as recurrent or progression of disease within 6 months of last platinum chemotherapy.~* May have had 1 additional cytotoxic or non-cytotoxic chemotherapy regimen.~* Must have adequate hematologic and hepatic function.~Exclusion Criteria:~* Previously received bevacizumab.~* History of other invasive malignancy with the exception of nonmelanoma skin cancer.~* ECOG performance status of 2, 3, or 4.~* Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study. Patient must be bevacizumab naïve.~* Blood pressure of \>150/100 mm Hg on antihypertensive medications.~* Prior history of hypertensive crisis or hypertensive encephalopathy.~* Diagnosed with unstable angina per NYHA or Grade 2 or greater congestive heart failure.~* History of myocardial infarction within 6 months of enrollment.~* History of stroke or transient ischemic attack within 6 months prior to study enrollment.~* Clinically significant vascular disease (e.g., aortic aneurysm, aortic dissection)or symptomatic peripheral vascular disease.~* Bleeding diathesis or coagulopathy.~* Presence of CNS or brain metastases.~* Pre-existing peripheral neuropathy of Grade ≥ 2.~* A major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study.~* A partial or complete small or large bowel obstruction demonstrated radiologically within 3 months prior to study enrollment.~* Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment.~* Positive pregnancy test or is lactating.~* History of abdominal fistula, GI perforation, or intra-abdominal abscess within 6 months prior to study enrollment.~* Serious, non-healing wound, ulcer, or bone fracture.~* Serious intercurrent medical or psychiatric illness, including serious active infection.~* Inability to comply with study and/or follow-up procedures.~* Life expectancy of less than 12 weeks.~* Proteinuria at screening as demonstrated by either:~* Urine protein:creatinine (UPC) ratio ≥ 1.0 at screening OR~* Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible).~* Known hypersensitivity to any component of bevacizumab.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete